Vir Biotechnology (VIR) said Thursday it has enrolled the first patient in a phase 3 study that will evaluate the efficacy and safety of its drug tobevibart in combination with elebsiran as a potential treatment for chronic hepatitis delta.

The trial is designed to provide the registrational data for submission to multiple regulatory agencies, the company said.

Chronic hepatitis delta is a severe inflammatory liver disease.

Shares were 0.5% higher in recent premarket activity.